TY  - JOUR

T1  - A Cost-Utility Analysis of Nilotinib for CML Patients Who Have Become Resistant to Imatinib.

JO  - Blood

PY  - 2007/11/16

AU  - Pilgrim H

AU  - Jewitt K

AU  - Ward S

ED  - 

DO  - DOI: 10.1182/blood.v110.11.5175.5175

PB  - American Society of Hematology

VL  - 110

IS  - 11

SP  - 5175

EP  - 5175

Y2  - 2024/12/21

ER  -